Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Griet Hoste, Laurence Slembrouck, Lynn Jongen, Kevin Punie, Tom Matton, Sara Vander Borght, Isabelle Vanden Bempt, Johan Menten, Hans Wildiers, Giuseppe Floris, Carlos L Arteaga, Patrick Neven

Research output: Contribution to journalArticle

Abstract

Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

Original languageEnglish (US)
JournalClinical Drug Investigation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Consultants
Breast Neoplasms
Pharmaceutical Preparations
fulvestrant

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Correction to : Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3). / Hoste, Griet; Slembrouck, Laurence; Jongen, Lynn; Punie, Kevin; Matton, Tom; Vander Borght, Sara; Vanden Bempt, Isabelle; Menten, Johan; Wildiers, Hans; Floris, Giuseppe; Arteaga, Carlos L; Neven, Patrick.

In: Clinical Drug Investigation, 01.01.2019.

Research output: Contribution to journalArticle

Hoste, Griet ; Slembrouck, Laurence ; Jongen, Lynn ; Punie, Kevin ; Matton, Tom ; Vander Borght, Sara ; Vanden Bempt, Isabelle ; Menten, Johan ; Wildiers, Hans ; Floris, Giuseppe ; Arteaga, Carlos L ; Neven, Patrick. / Correction to : Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3). In: Clinical Drug Investigation. 2019.
@article{f1de5d8fdafd452591839ad9913f5d71,
title = "Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)",
abstract = "Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.",
author = "Griet Hoste and Laurence Slembrouck and Lynn Jongen and Kevin Punie and Tom Matton and {Vander Borght}, Sara and {Vanden Bempt}, Isabelle and Johan Menten and Hans Wildiers and Giuseppe Floris and Arteaga, {Carlos L} and Patrick Neven",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s40261-019-00748-x",
language = "English (US)",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Correction to

T2 - Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

AU - Hoste, Griet

AU - Slembrouck, Laurence

AU - Jongen, Lynn

AU - Punie, Kevin

AU - Matton, Tom

AU - Vander Borght, Sara

AU - Vanden Bempt, Isabelle

AU - Menten, Johan

AU - Wildiers, Hans

AU - Floris, Giuseppe

AU - Arteaga, Carlos L

AU - Neven, Patrick

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

AB - Dr. Arteaga serves on an Advisory Board for Novartis and was a consultant for AstraZeneca from 2015 to 2016. All other authors declare that they have no competing interests.

UR - http://www.scopus.com/inward/record.url?scp=85060035354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060035354&partnerID=8YFLogxK

U2 - 10.1007/s40261-019-00748-x

DO - 10.1007/s40261-019-00748-x

M3 - Article

C2 - 30637612

AN - SCOPUS:85060035354

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

ER -